Life-prolonging drug for advanced ovarian cancer gets go-ahead in England
Elahere is first new drug for chemotherapy-resistant ovarian cancer to be approved by NHS for 20 yearsHundreds of women with hard-to-treat ovarian cancer can now be offered a new life-prolonging treatment, after NHS England approved its introduction. It is the first new drug for resistant ovarian cancer to be approved for more than 20 years.Ovarian is the 18th most common type of cancer globally, affecting more than 300,000 women a year. More than three-quarters of patients are diagnosed at an advanced stage, making it harder to treat. Continue reading…
Elahere is first new drug for chemotherapy-resistant ovarian cancer to be approved by NHS for 20 yearsHundreds of women with hard-to-treat ovarian cancer can now be offered a new life-prolonging treatment, after NHS England approved its introduction. It is the first new drug for resistant ovarian cancer to be approved for more than 20 years.Ovarian…
Elahere is first new drug for chemotherapy-resistant ovarian cancer to be approved by NHS for 20 yearsHundreds of women with hard-to-treat ovarian cancer can now be offered a new life-prolonging treatment, after NHS England approved its introduction. It is the first new drug for resistant ovarian cancer to be approved for more than 20 years.Ovarian is the 18th most common type of cancer globally, affecting more than 300,000 women a year. More than three-quarters of patients are diagnosed at an advanced stage, making it harder…
The full story continues on The Guardian.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.